KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Treasury Shares (2016 - 2025)

Biomarin Pharmaceutical's Treasury Shares history spans 16 years, with the latest figure at $5.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 1078.87% year-over-year to $5.2 million, compared with a TTM value of $5.2 million through Dec 2025, up 1078.87%, and an annual FY2025 reading of $5.2 million, up 1078.87% over the prior year.
  • Treasury Shares for Q4 2025 was $5.2 million at Biomarin Pharmaceutical, up from $443340.0 in the prior quarter.
  • The five-year high for Treasury Shares was $5.2 million in Q4 2025, with the low at $85010.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $1.9 million, with a median of $419730.0 recorded in 2022.
  • Year-over-year, Treasury Shares skyrocketed 1087.47% in 2023 and then tumbled 90.57% in 2024.
  • Tracing BMRN's Treasury Shares over 5 years: stood at $350860.0 in 2021, then increased by 12.9% to $396120.0 in 2022, then skyrocketed by 1087.47% to $4.7 million in 2023, then tumbled by 90.57% to $443340.0 in 2024, then skyrocketed by 1078.87% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Treasury Shares are $5.2 million (Q4 2025), $443340.0 (Q4 2024), and $4.7 million (Q4 2023).